Jesse G. Dixon

Also affiliated with Alliance for Clinical Trials in Oncology, Mayo Clinic in Arizona, Alliance Data (United States), VA Loma Linda Healthcare System, Mayo Clinic in Florida

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 10 papers. Top paper: “Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur)”.

Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur)

BMC Cancer(2024)10.1186/s12885-024-11899-2

N/A

0.324DataRank · unranked

4 citations

Eric D. Miller, Qian Shi, Jesse G. Dixon, Sepideh Gholami, Sarah B. White +13 more

Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma

Neuro-Oncology(2025)10.1093/neuonc/noaf156

N/A

0.273DataRank · unranked

5 citations

Jesse G. Dixon, S. Keith Anderson, Jann N. Sarkaria, Paul D. Brown, Elizabeth Yan +10 more

Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)

JCO Oncology Advances(2025)10.1200/oa-25-00099

N/A

0.104DataRank · unranked

1 citations

Qian Shi, Kenneth P. Olive, Eric A. Collisson, Jesse G. Dixon, Mike Cusnir +8 more

Alliance A022101: A pragmatic, randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: Evaluating Radiation, Ablation, and Surgery (ERASur).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps3629

N/A

0DataRank · unranked

1 citations

Paul B. Romesser, Qian Shi, Jesse G. Dixon, Sepideh Gholami, Sarah B. White +12 more

Alliance for Clinical Trials in Oncology (Alliance) trial A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur)

Research Square(2023)10.21203/rs.3.rs-3773522/v1

N/A

0DataRank · unranked

1 citations

Eric D. Miller, Qian Shi, Jesse G. Dixon, Sepideh Gholami, Sarah B. White +13 more

Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance A071102).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.2001

N/A

0DataRank · unranked

18 citations

Karla V. Ballman, Sani H. Kizilbash, Erik P. Sulman, Caterina Giannini, Sandeep H. Mashru +11 more

Alliance A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation, ablation, and surgery (ERASur).

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.tps3633

N/A

0DataRank · unranked

0 citations

Kathryn Hitchcock, Qian Shi, Jesse G. Dixon, Sepideh Gholami, Sarah B. White +12 more

Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials

JNCI Journal of the National Cancer Institute(2021)10.1093/jnci/djab187

N/A

0DataRank · unranked

16 citations

Mohamed E. Salem, Jesse G. Dixon, Zhaohui Jin, Romain Cohen, Aimery DeGramont +16 more

Alliance A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation, ablation, and surgery (ERASur).

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.tps3634

N/A

0DataRank · unranked

0 citations

Kathryn Hitchcock, Qian Shi, Jesse G. Dixon, Sepideh Gholami, Sarah B. White +12 more

Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4099

N/A

0DataRank · unranked

1 citations

Jesse G. Dixon, Hiral D. Parekh, Steven R. Alberts, Greg Yothers, Carmen J. Allegra +15 more